Data suggest that cabozantinib and pembrolizumab can be effective in patients with advanced gastric or gastroesophageal junction cancer whose disease is resistant or refractory to immune checkpoint ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

Health Canada has approved Merck’s KEYTRUDA (pembrolizumab), an anti-programmed ... chemotherapy as a first-line treatment for adult gastric cancer patients. The combination treatment is ...

ALPMF's expanding lineup of cancer drugs, including zolbetuximab, positions them for substantial market growth and potential appreciation.

PD-1 inhibitor Keytruda (pembrolizumab) has been cleared in ... "Patients in the EU diagnosed with HER2-positive advanced gastric cancer face an aggressive disease associated with a poor prognosis ...

This Industry Satellite Symposium was presented at the European Society for Medical Oncology (ESMO) Congress 2024, held in ...

Keytruda (pembrolizumab) is a prescription drug ... (Cytoreductive treatment lowers the number of cancer cells.) Stomach cancer: Keytruda is prescribed to adults as a first-choice treatment ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 in ...

Dr. Brian Slomovitz: Thanks, Shannon. Dr. Shannon Westin: And listeners. Thank you all for taking the time to hear about endometrial cancer. Again, this was “Pembrolizumab or Placebo, Plus Adjuvant ...

A life-extending drug for advanced cervical cancer will be made available to NHS patients in England, like it is in Scotland, new recommendations say. Pembrolizumab can mean extra months of life ...

and PFS compared to concurrent CRT alone for newly diagnosed patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer.